熱門資訊> 正文
TX 45引用Raymond James的Tectual开局表现优于Raymond James
2024-11-21 01:45
- Raymond James has started coverage of Tectonic Therapeutic (NASDAQ:TECX) with an outperform rating, citing its drug candidate TX45.
- The investment firm said it believes the company's relaxin mimetic drug candidate TX45 for the treatment of group 2 pulmonary hypertension is potentially best-in-class. It noted that relaxin mimetics remains an active area for Big Pharma R&D, citing Eli Lilly (LLY) and AstraZeneca (AZN).
- “We believe TECX’s platform has enabled them to design a molecule with superior PK/PD vs the competition, and if successful, we think TX45 could become a multi-billion dollar drug,” the firm added.
- Raymond James said it sees several value inflection points for the stock over the next approximately 12 to 24 months. The firm set its price target for the stock at $65.
More on AVROBIO
- Tectonic Therapeutic: Interesting CV Disease Drug Developer
- Tectonic draws bullish view at Wells Fargo on lead asset
- Historical earnings data for AVROBIO
- Financial information for AVROBIO
推薦文章
美股機會日報 | 特朗普放大招！9萬億養老金即將殺入加密市場；美聯儲主席候選人支持7月降息
一周財經日曆 | 特斯拉、谷歌財報重磅來襲！維立志博將於下周五登陸港交所
一圖看懂 | 港股上半年IPO募資額登頂全球！中籤就賺一萬港幣的「大肉籤」你參與了嗎？
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
創新葯行情徹底爆發！維立志博-B打新半日孖展超購130倍，凍資近150億港元
新股申購 | 維立志博-B入場費3535.30港元！引入騰訊、易方達等基石投資者
7月財報預告丨迎關税考驗！特斯拉、臺積電放榜在即，美股能否守住漲勢？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
